Safety and Immunologic Activity of Multiple Infusions of APN401

What we are studying

Participants are being asked to take part in this study because they have been diagnosed with a cancer that has spread and cannot be surgically removed. A phase I clinical trial to determine the toxicities of a single intravenous administration of APN401 established feasibility and safety. This clinical trial will examine multiple infusions and also provide an initial estimate of immunologic activity. The overall goal is to determine if there is sufficient evidence of safety and immunologic activity to proceed to phase II clinical trials, alone or in combination with other antitumor agents.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnosed with a cancer that has spread and cannot be surgically removed

What is involved

  • Medical History
  • Physical Exam
  • Assessment of cancer to include CT scans
  • Blood test to check blood cell counts and pregnancy.

Compensation

Parking will be validated for study-related visits

Contact Information

Study Coordinator
Angela Howell, RN
Email
anhowell@wakehealth.edu
Phone
336-713-3155
Principal Investigator
Pierre Trizzoi, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.